Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down – Here’s What Happened

Genmab A/S (OTCMKTS:GNMSF)’s share price gapped down prior to trading on Friday . The stock had previously closed at $269.50, but opened at $258.1201. Genmab A/S shares last traded at $258.1201, with a volume of 3 shares changing hands.

Genmab A/S Trading Down 4.2%

The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The business’s fifty day simple moving average is $270.06 and its two-hundred day simple moving average is $298.26. The stock has a market capitalization of $15.89 billion, a P/E ratio of 19.47 and a beta of 0.82.

Genmab A/S (OTCMKTS:GNMSF) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $3.10 by ($2.55). Genmab A/S had a net margin of 21.05% and a return on equity of 15.34%. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.